Medizinische Universität Graz - Research portal
Steiner Daniel |
** = Publications listed in SCI/SSCI/Pubmed
2024
Full paper/article (Journal)
** Englisch, C; Moik, F; Steiner, D; Starzer, AM; Berghoff, AS; Preusser, M; Pabinger, I; Ay, C
Bleeding events in patients with cancer: incidence, risk factors, and impact on prognosis in a prospective cohort study.
Blood. 2024; 144(22):2349-2359
Doi: 10.1182/blood.2024025362
Web of Science
PubMed
FullText
FullText_MUG
** Englisch, C; Nopp, S; Moik, F; Steiner, D; Starzer, AM; Fritzer-Szekeres, M; Preusser, M; Berghoff, AS; Pabinger, I; Ay, C
Growth Differentiation Factor-15 Predicts Major Bleeding in Cancer Patients: Results From the Vienna CAT-BLED Study.
JACC CardioOncol. 2025; 7(2):141-152
Doi: 10.1016/j.jaccao.2024.11.007
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2022
Short report/Letter
** Steiner, D; Smolle, MA; Brcic, I; Leithner, A
Rhabdomyosarcoma and pleomorphic sarcoma in the same location : Recurrence or new entity?
Wien Klin Wochenschr. 2022; 134(1-2):76-79
Doi: 10.1007/s00508-021-01872-5
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2021
Full paper/article (Journal)
** Suppan, C; Posch, F; Mueller, HD; Mischitz, N; Steiner, D; Klocker, EV; Setaffy, L; Bargfrieder, U; Hammer, R; Hauser, H; Jost, PJ; Dandachi, N; Lax, S; Balic, M
Patterns of Recurrence after Neoadjuvant Therapy in Early Breast Cancer, according to the Residual Cancer Burden Index and Reductions in Neoadjuvant Treatment Intensity.
Cancers (Basel). 2021; 13(10):
Doi: 10.3390/cancers13102492
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
** Suppan, C; Steiner, D; Klocker, EV; Posch, F; Henzinger, E; Muller, HD; Stoger, H; Dandachi, N; Balic, M
Safety and Clinical Evaluation of Dual Inhibition with Pertuzumab and Trastuzumab Biosimilar SB3 in HER2-Positive Breast Cancer Patients
BREAST CARE. 2021;
Doi: 10.1159/000513766
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Abstract (Journal)
** Suppan, C; Steiner, D; Klocker, VE; Posch, F; Henzinger, EC; Stoeger, H; Dandachi, N; Balic, M
Safety and clinical evaluation of dual inhibition with pertuzumab and trastuzumab in HER-2-positive breast cancer patients.
J CLIN ONCOL. 2020; 38(15):
[Onlinepräsentation]
Web of Science
FullText